According to MarketsandMarkets™, the global Oligonucleotide CDMO Market is witnessing rapid expansion, projected to grow from USD 2.51 billion in 2024 to USD 6.73 billion by 2029, at a CAGR of 21.8%. This growth reflects a broader shift toward outsourcing complex drug development and manufacturing processes, particularly for advanced oligonucleotide-based therapeutics.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=227700087
Browse
- 270 Market Data Tables
- 56 Figures
- 254 Pages and in-depth TOC on “ Oligonucleotide CDMO Market – Global Forecast to 2029”.
What is fueling this high-growth trajectory?
The increasing focus on the development and commercialization of oligonucleotide-based therapies is a primary driver. As pharmaceutical and biotechnology companies accelerate innovation in gene-targeted treatments, they are increasingly relying on Contract Development and Manufacturing Organizations (CDMOs) to streamline production, reduce costs, and navigate complex regulatory environments.
Why is outsourcing becoming critical?
Oligonucleotide manufacturing requires specialized expertise, advanced infrastructure, and stringent regulatory compliance. CDMOs offer scalable capabilities, enabling companies to move efficiently from early-stage development to commercial production. This shift is particularly important in the era of precision medicine, where therapies are tailored to specific genetic profiles.
By application, the therapeutic segment dominated the market in 2023. What explains this dominance? Oligonucleotide therapies are increasingly being developed for a wide range of indications, including oncology, neurological disorders, and infectious diseases. Their ability to target specific genetic mutations makes them a cornerstone of personalized medicine, driving demand for large-scale manufacturing support.
From a manufacturing stage perspective, the commercial segment accounted for the largest share during the forecast period. Why does commercial manufacturing lead? Unlike clinical-scale production, commercial manufacturing is continuous and long-term, often spanning the entire lifecycle of a drug. With a growing number of regulatory approvals for oligonucleotide-based therapies, the demand for large-scale, repeat production has surged—making commercial manufacturing a major revenue generator for CDMOs.
Additionally, CDMOs bring critical advantages such as advanced production facilities, regulatory expertise, and the ability to handle complex synthesis processes at scale. These capabilities are essential as the industry transitions from experimental therapies to mainstream clinical use.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=227700087
Where is the center of gravity for innovation and growth?
Regionally, North America held the largest share of the oligonucleotide CDMO market in 2023, supported by the presence of leading players and strong biopharmaceutical infrastructure. Meanwhile, Asia Pacific is emerging as the fastest-growing region. What is driving this shift? Increasing investments by global companies, expanding domestic capabilities, and supportive government policies promoting R&D are positioning Asia Pacific as a key growth hub.
Despite strong growth prospects, the market faces certain constraints. High volumes of organic and aqueous waste generated during oligonucleotide synthesis, along with stringent regulatory requirements, present environmental and compliance challenges for manufacturers. Addressing these issues will be critical for sustainable market expansion.
Who are the key players shaping competition and innovation in this market?
Leading players in the oligonucleotide CDMO market include Thermo Fisher Scientific Inc., Lonza, Agilent Technologies, Inc., Kaneka Eurogentec S.A., Ajinomoto Co., Inc., Aurigene Pharmaceutical Services Ltd., Bachem, Syngene International Limited, PolyPeptide Group, WuXi AppTec, EUROAPI, Eurofins Scientific, GenScript, and Danaher Corporation. These companies are focusing on capacity expansion, strategic collaborations, and technological advancements to strengthen their market positions.
Related Reports:
Genomics Market – Global Forecast to 2030
Next Generation Sequencing Market– Global Forecast to 2030
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com